Question for holders about exclusivity., page-3

I agree with TB’s comments.

But perhaps I might add that PYCs Cell Penetrating Peptides and method of delivery of the active mRNA to replace the defective gene product are very efficient and well targeted. So, even if a competitor has a replacement mRNA their delivery system might not work as well, so higher doses might be needed. This increases risk of adverse effects.
Another possibility is that their treatment might have a shorter half-life and thus require more frequent dosage.
So there will be several factors to be weighed up before choosing the “best” treatment.
All just IMO, sitting in warm sun in a huge rose garden. What pleasure! And knowing that perhaps we will find out about Cohort 4 tomorrow (or soon) makes it even better.